FDA Expands Pediatric Roflumilast Use - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA Expands Pediatric Roflumilast Use

The expanded indication is supported by pharmacokinetic, safety, tolerability, exploratory efficacy, and long-term safety data from studies in children aged 2 to 5 years.

  • By

  • Kathryn Wighton

  • June 30, 2026

  • 3 min

Share

  • 1

    The FDA has approved roflumilast (ZORYVE) cream 0.3% for treating plaque psoriasis in pediatric patients aged 2 years and older.

  • 2

    Roflumilast was previously approved for adults and children aged 6 years and older at a lower 0.15% dose.

  • 3

    The approval was based on a study evaluating pharmacokinetics, safety, and efficacy in children aged 2 to 5 years.

  • 4

    Roflumilast cream is contraindicated in patients with moderate to severe liver impairment.

  • 5

    Common adverse reactions in trials included diarrhea, headache, insomnia, and application-site pain.

Original Source(s)

FDA Expands Pediatric Roflumilast Use

  • by Kathryn Wighton

  • June 30, 2026

Related Content

Immunobiological Therapy in Moderate-to-Severe Psoriasis: A Retrospective Cohort Study Investigating the Effects of Inadequate Therapeutic Compliance on Drug Survival

Understanding Social Drivers of Health Among US Adults with Psoriasis from Different Races and Ethnicities

GLP-1 RAs May Ease Psoriasis, PsA Data Limited

Published evidence linked liraglutide and semaglutide to improvements in psoriasis severity, inflammatory markers, and metabolic outcomes, while evidence in psoriatic arthritis remained sparse.